I was crazy enough to join a busy Integrative Medicine Fellowship in the middle of my cardiology training, but I am glad I did. It was worth it.! One more fellowship to go. #IntegrativeMedicine #IntegrativeCardiology #AIHM

👀 @Stanford_HF surpassed 2⃣5⃣0⃣0⃣🫀transplants in program history this month‼️ Congratulations to the entire team that makes this possible 🙌🎆🥳 @Stanford @stanfordctsurg @StanfordMed @StanCVFellows @StanfordCVI @ISHLT @HFSA @tcccop @KiranKhush1 @EldrinL @Erik_Henricksen

(10/10) HELIOS-B shows RNAi therapy can significantly improve survival and HF outcomes in ATTR-CM. Vutrisiran’s success establishes TTR gene silencing as a viable strategy alongside stabilizers, heralding a new era for #Amyloidosis care. #CardioTwitter #JACC

(9/10) #Vutrisiran (SC q3mo) is poised to join tafamidis as a therapy for ATTR-CM. Its q3-month dosing is more convenient than patisiran (IV q3w). A silencer + stabilizer combination might offer added benefit, but needs confirmation in future trials. #Amyloidosis

(8/10) Patisiran (APOLLO-B, 12-mo IV RNAi) improved 6MWT by ~15 m and KCCQ score by ~4 points vs placebo. But 12-mo mortality was similar (3% vs 4%), since APOLLO-B wasn’t powered or long enough to show a survival benefit.

(7/10) Tafamidis (ATTR-ACT) improved outcomes in ATTR-CM: 30-mo mortality 29.5% vs 42.9% on placebo, and fewer CV hospitalizations. https://t.co/hJteNQn5d7 Vutrisiran’s ~36% mortality risk reduction is comparable, achieved via TTR gene silencing vs TTR stabilization.

(6/10) Vutrisiran’s benefit was evident regardless of tafamidis use. Outcomes improved similarly even in the ~40% of patients on tafamidis, suggestsing potential additive effects, though experts caution not to adopt combination therapy yet without more evidence.

(5/10) Vutrisiran lowered risk of HF worsening by ~34% (HR 0.66). 6MWT decline was 26.5 m less vs placebo, indicating better preserved exercise capacity. KCCQ and NT-proBNP also improved with vutrisiran. https://t.co/2u3hGlm8X0

(4/10) Vutrisiran significantly improved survival and reduced CV events. All-cause mortality was ~36% lower vs placebo (HR 0.64). CV mortality dropped ~33% (HR 0.67). The composite of CV death + events was reduced by 28% (HR 0.72, p = 0.01) https://t.co/ptVOWymN5V

(3/10) 655 ATTR-CM patients (hereditary or wild-type) were randomized 1:1 to vutrisiran 25 mg q3mo vs placebo; follow-up up to ~3 yrs. ~40% were on tafamidis at baseline (continued if already on). Primary endpoint: all-cause mortality + recurrent CV events.

(2/10) HELIOS-B was a Phase 3 trial of #vutrisiran, a subcutaneous #RNAi therapeutic, in ATTR-CM. It showed significant reductions in mortality and CV events vs placebo, marking a new milestone in #Amyloidosis care.

(1/10) 🧬Vutrisiran, a subcutaneous RNAi therapy, significantly reduces all-cause mortality & CV events in the HELIOS-B trial - benefits seen even with background tafamidis. #CardioTwitter #ATTR #HeartFailure #RNAi #JACC

Almost 6 years later and I’m still using a lot of the skills I learned in the #Stanford25 sessions.

The end of another chapter. Ready for a much needed vacation prior to starting AHFTC fellowship.

More bad news for Advanced Heart Failure and Transplant Cardiology #NRMP match: Of 75 programs participating in match n=21 (28%) filled. Of 127 positions offered, n=61 (48%) filled. There will only be n=61 AHFTC trainees in the US in 2025-2026 academic year. #ShrinkingWorkforce

Match Day 2019 vs Match Day 2024. I remember being lost for words when I matched into Stanford for Internal Medicine as a med student. I’m even more excited to be going back for Advanced Heart Failure and Transplant Cardiology! @stanford_HF @StanfordMedRes @ScrippsCVFellow

🥳🎉 @Stanford_HF @KiranKhush1 and @SunnyVMD welcome its 2025-26 HF fellows: @CardiBeatMD from @ScrippsCVFellow @BGomes_1905 from @Stanford @rudyunni from @UofTCardio Looking forward to working with our newest colleagues‼️ @EldrinL @euanashley @StanCVFellows @StanfordCVI

3rd poster at a major conference in less than 6 months. Your future is bright my friend. @JoshuaMedEd MS3, future cardiologist! #AHA24

In the city where my dreams of being a cardiologist began… a city that nurtured me from the south side housing projects to a future leader in the field. Chicago will always hold a special place in my heart! Until next time. #AHA24 #Chitown #cardiology

What an amazing weekend at the @CVRx_Inc #ASCENDHF Fellow Summit! Also enjoyed the public speaking workshop!